Last reviewed · How we verify
Upadacitinib (ABT-494)
Upadacitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a key role in the inflammatory response.
Upadacitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a key role in the inflammatory response. Used for Rheumatoid arthritis, Psoriatic arthritis, Ulcerative colitis.
At a glance
| Generic name | Upadacitinib (ABT-494) |
|---|---|
| Also known as | ABT-494, RINVOQ |
| Sponsor | AbbVie |
| Drug class | JAK inhibitor |
| Target | JAK1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting JAK enzymes, upadacitinib reduces the production of pro-inflammatory cytokines, thereby decreasing inflammation and modulating the immune response. This mechanism of action is thought to contribute to its therapeutic effects in various inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Ulcerative colitis
Common side effects
- Upper respiratory tract infection
- Nausea
- Headache
Key clinical trials
- A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (PHASE3)
- A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (PHASE3)
- A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (PHASE3)
- A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis (PHASE3)
- Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK) (PHASE3)
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Upadacitinib (ABT-494) CI brief — competitive landscape report
- Upadacitinib (ABT-494) updates RSS · CI watch RSS
- AbbVie portfolio CI